已收盤 02-06 16:00:00 美东时间
+0.850
+4.93%
今日重点评级关注:杰富瑞:维持ImmunityBio Inc Ordinary Shares"买入"评级,目标价从8美元升至9美元;B. Riley证券:维持WAVE Life Sciences"买入"评级,目标价从19美元升至37美元
2025-12-15 15:30
JP Morgan analyst Cory Carpenter maintains EverQuote (NASDAQ:EVER) with a Overweight and raises the price target from $30 to $32.
2025-12-13 03:05
今日重点评级关注:瑞银:维持Syndax Pharmaceuticals"买入"评级,目标价从35美元升至38美元;HC Wainwright & Co.:维持Benitec Biopharma"买入"评级,目标价从28美元升至35美元
2025-11-05 10:35
JP Morgan analyst Cory Carpenter maintains EverQuote (NASDAQ:EVER) with a Overweight and raises the price target from $29 to $30.
2025-11-04 23:03
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据EverQuote 2025年第三季度业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 总营收达到1.739亿美元,同比增长20%,创季度新高 - 汽车保险营收1.576亿美元,同比增长超过21%,占总营收主要部分 - 房屋及租户保险营收1,630万美元,同比增长15% **盈利能力:** - 净利润1,890万美元,创历史新高,较去年同期的1,160万美元大幅增长 - 调整后EBITDA达到2,510万美元,同比增长33%,增幅显著超过营收增长率 - 调整后EBITDA利润率为14.4%,体现出运营杠杆效应和效
2025-11-04 12:31
An update from Evergold Corp ( ($TSE:EVER) ) is now available. Evergold Corp. h...
2025-10-29 19:48
今日重点评级关注:Ascendiant Capital:维持GRI Bio"买入"评级,目标价从34美元升至35美元;Ascendiant Capital:维持Atossa Therapeutics"买入"评级,目标价从7.5美元升至7.75美元
2025-09-23 09:52
Raymond James analyst Aaron Kessler downgrades EverQuote (NASDAQ:EVER) from Strong Buy to Outperform and lowers the price target from $35 to $30.
2025-09-23 00:28
Evergold Corp ( ($TSE:EVER) ) just unveiled an announcement. Evergold Corp. ann...
2025-09-15 19:57